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Background and aims: Remnant-like particle cholesterol (RLP-C) is atherogenic and may increase
atherosclerotic cardiovascular disease risk. Icosapent ethyl is a high-purity prescription eicosapentaenoic
acid ethyl ester (approved as an adjunct to diet to reduce triglyceride [TG] levels in adult patients with
TGs 500 mg/dL [5.65 mmol/L] at 4 g/day). In the MARINE and ANCHOR studies, icosapent ethyl
reduced TG and other atherogenic lipid parameter levels without increasing low-density lipoprotein
cholesterol (LDL-C) levels. This exploratory analysis evaluated the effects of icosapent ethyl on calculated
and directly measured RLP-C.
Methods: MARINE (TGs 500 and 2000 mg/dL [5.65 mmol/L and 22.6 mmol/L]) and ANCHOR (TGs
200 and <500 mg/dL [2.26 and <5.65 mmol/L] despite statin-controlled LDL-C) were phase 3, 12-
week, double-blind studies that randomized adult patients to icosapent ethyl 4 g/day, 2 g/day, or pla-
cebo. This analysis assessed median percent change from baseline to study end in directly measured
(immunoseparation assay) RLP-C levels (MARINE, n ¼ 218; ANCHOR, n ¼ 252) and calculated RLP-C levels
in the full populations.
Results: Icosapent ethyl 4 g/day signiﬁcantly reduced directly measured RLP-C levels 29.8% (p ¼ 0.004)
in MARINE and 25.8% (p ¼ 0.0001) in ANCHOR versus placebo, and also reduced directly measured RLP-
C levels to a greater extent in subgroups with higher versus lower baseline TG levels, in patients receiving
statins versus no statins (MARINE), and in patients receiving medium/higher-intensity versus lower-
intensity statins (ANCHOR). Strong correlations were found between calculated and directly measured
RLP-C for baseline, end-of-treatment, and percent change values in ANCHOR and MARINE (0.73e0.92;
p < 0.0001 for all).
Conclusions: Icosapent ethyl 4 g/day signiﬁcantly reduced calculated and directly measured RLP-C levels
versus placebo in patients with elevated TG levels from the MARINE and ANCHOR studies.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Triglyceride (TG)-rich apolipoprotein B (ApoB)-containing lipo-
proteins released from the intestine or liver undergo lipolysis at thee).
Ireland Ltd. This is an open accesssurface of endothelial cells, creating TG-poor and cholesterol-rich
remnant particles (e.g., chylomicron remnants in the non-fasting
state and dense subfractions of very-low-density lipoprotein
[VLDL] and intermediate-density lipoprotein in the fasting and
non-fasting states) [1,2]. An indirect approximation of remnant li-
poprotein cholesterol (RLP-C) levels can be readily achieved by
subtracting the cholesterol carried by low-density lipoproteins
(LDL-C) from the cholesterol carried by all atherogenic lipoproteins,
as reﬂected by non-high-density lipoprotein cholesterol (non-HDL-
C), which in turn is calculated by subtracting high-densityarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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RLP-C¼ TC [HDL-C] [LDL-C]) [3]. More directmeasures of RLP-C
levels include immunoseparation and vertical auto proﬁle testing
[4]. Direct isolation of remnants allows for a more accurate mea-
surement of the atherogenic cholesterol within the TG-rich lipo-
protein subpopulation than calculated RLP-C, but such direct
measures are not readily available to practicing clinicians [5].
High RLP-C levels appear to be a risk factor for atherosclerotic
cardiovascular disease in patients with coronary artery disease,
diabetes, or metabolic syndrome, as well as those on statin therapy
[6e10]. Overall, current evidence suggests that elevated remnant
cholesterol levels are one of the causal factors of residual ischemic
heart disease risk [3] and cardiovascular disease [11].
Icosapent ethyl (Vascepa®; Amarin Pharma Inc., Bedminster, NJ,
USA) is a high-purity prescription form of eicosapentaenoic acid
(EPA) ethyl ester approved by the US Food and Drug Administration
as an adjunct to diet to reduce TG levels in adult patients with
severe hypertriglyceridemia (500 mg/dL [5.65 mmol/L]) at a
dose of 4 g/day [12]. Two randomized, double-blind, placebo-
controlled, multicenter, phase 3 studies (MARINE and ANCHOR)
demonstrated the efﬁcacy and safety of icosapent ethyl 2 g/day and
4 g/day. In both studies, icosapent ethyl 4 g/day signiﬁcantly
reduced TG levels and improved other lipid parameters including
non-HDL-C and ApoB, without raising LDL-C levels compared with
placebo [13,14]. To gain a better understanding of the lipid effects of
icosapent ethyl, this exploratory analysis evaluated the impact of
icosapent ethyl on directly measured and calculated RLP-C levels in
patients from the MARINE and ANCHOR studies.
2. Materials and methods
2.1. Study design
Details of the MARINE and ANCHOR studies have been pub-
lished previously [13,14]. Brieﬂy, both studies included a 4e6 week
lead-in period of diet, lifestyle, and medication stabilization with
washout of prohibited lipid-altering medications. Both studies
randomized patients aged >18 years with qualifying lipid levels
(TGs 500 and 2000 mg/dL [5.65 and 22.6 mmol/L] in MA-
RINE; statin-stabilized TGs 200 and <500 mg/dL [2.26 and
<5.65 mmol/L] and LDL-C 40 and <100 mg/dL [1.04 and
<2.59 mmol/L] in ANCHOR) to receive icosapent ethyl 4 g/day,
icosapent ethyl 2 g/day, or matching placebo during a 12-week
double-blind treatment period. The MARINE study permitted, but
did not require stable statin therapy with or without ezetimibe.
Enrollment in the ANCHOR study required patients to be at high
risk of cardiovascular disease as deﬁned by the National Cholesterol
Education Program Adult Treatment Panel III guidelines [15] and on
a stable statin dose (atorvastatin, rosuvastatin, or simvastatin with
or without ezetimibe) prior to baseline initiation of icosapent ethyl
or placebo. The protocols for each study were approved by the
appropriate institutional review boards, and all patients provided
written informed consent before enrollment [13,14].
2.2. Assessments and measurements
The MARINE and ANCHOR studies measured serum RLP-C as a
prespeciﬁed exploratory endpoint using an immunoseparation
assay from Polymedco (Cortlandt, NY, USA) on a Daytona chemistry
analyzer (Randox Laboratories, Crumlin, UK) [16e18]. A central
laboratory measured other lipid parameters as previously
described, including LDL-C measurements by preparative ultra-
centrifugation (beta-quantiﬁcation) [13,19]. Plasma lipid parameter
evaluations included patients from the intent-to-treat population,
deﬁned as all randomized patients who had a baseline TGmeasurement, received 1 dose of the study drug, and had 1
post-randomization efﬁcacy measurement.
2.3. Statistical analysis
Medians and interquartile ranges of RLP-C were calculated for
each treatment group at baseline and at week 12, and for the
percent changes from baseline. The median differences in percent
changes from baseline for RLP-C were estimated between the ico-
sapent ethyl and placebo groups using the Hodges-Lehmann
method, with the Wilcoxon rank sum test used to calculate p
values. Subgroup analyses were conducted by baseline TG level in
each study, by statin use in the MARINE study, and by the statin
intensity (lower vsmedium/higher) in the ANCHOR study. This post
hoc analysis computed Pearson correlation coefﬁcients to assess
the relationships between calculated RLP-C and directly measured
RLP-C for baseline, week 12, and percent change from baseline
values. Each analysis utilized pooled data from the icosapent ethyl
treatment and placebo groups. A p value of 0.05 was the pre-
speciﬁed alpha for signiﬁcance for exploratory endpoints in the
MARINE and ANCHOR studies and was used in all analyses,
including post hoc analyses in this report. The formula of RLP-C (TC
e [HDL-C] e [LDL-C]; LDL-C being measured or calculated) was
employed for correlation analyses involving calculated RLP-C levels
[3]. For these RLP-C calculations, LDL-C was either directly
measured by preparative ultracentrifugation (beta-quantiﬁcation)
or, when applicable, calculated. When calculated LDL-C was
included in the RLP-C equation, the Friedewald equation (LDL-
C ¼ TC  [HDL-C]  [TG/5]) was applied, but only for patients with
TG levels <400 mg/dL (<4.52 mmol/L) [20]. When applicable,
resulting calculated RLP-C values are reported for both LDL-C
methods.
3. Results
3.1. Patients
Baseline demographics and lipid parameters were comparable
among treatment groups within each study (Table 1). In MARINE,
57 of 229 patients (25%) were receiving statin therapy, whereas in
ANCHOR, all 702 patients were on statins, of whom 654 (93%) were
on medium- or higher-intensity statin regimens (deﬁnitions of
medium- and higher-intensity statin regimens are listed in the
legend of Table 2). An immunoseparation assay was used to assess
total RLP-C levels in MARINE and ANCHOR. In MARINE, RLP-C
measurements were available from 218 patients (95% of study
cohort); in ANCHOR, as prespeciﬁed in the study protocol, RLP-C
measurements were to be conducted in (approximately) the ﬁrst
240 patients enrolled (actual n ¼ 252; 36% of study cohort).
Within each study, treatment groups showed comparable me-
dian baseline levels of TGs, non-HDL-C, LDL-C, VLDL-C, VLDL-TG,
and ApoB in the subset of patients with RLP-C measurements
(Table 1) as well as in the intent-to-treat populations of each study
[13,14]. Each study also had comparable median RLP-C levels at
baseline across treatment groups, ranging from 43.0 to 47.0 mg/dL
(1.11e1.22 mmol/L) in MARINE and from 13.5 to 15.0 mg/dL
(0.35e0.39 mmol/L) in ANCHOR (Table 2).
3.2. MARINE
At the approved dose of 4 g/day, icosapent ethyl signiﬁcantly
reduced median levels of directly measured RLP-C by 29.8%
(p ¼ 0.004) (Fig. 1 and Table 2) versus placebo. When evaluated by
statin use, icosapent ethyl 4 g/day signiﬁcantly reduced directly
measured RLP-C levels by 21.4% in patients not receiving statins
Table 1
Baseline characteristics (randomized populations) and baseline lipid parameters (patients from ITT populations with RLP-C measurements).
Icosapent ethyl 4 g/day Icosapent ethyl 2 g/day Placebo
Baseline characteristics
MARINE n ¼ 77 n ¼ 76 n ¼ 76
Age, mean (SD), y 51.9 (10.27) 53.4 (9.34) 53.4 (8.34)
Male, n (%) 59 (77) 58 (76) 58 (76)
Weight, mean (SD), kg 93.2 (18.27) 92.1 (15.57) 93.0 (16.92)
BMI, mean (SD), kg/m2 30.4 (4.29) 30.8 (4.24) 31.0 (4.25)
Diabetes, n (%) 22 (29) 20 (26) 21 (28)
Statin use, n (%) 20 (26) 19 (25) 18 (24)
ANCHOR n ¼ 233 n ¼ 236 n ¼ 233
Age, mean (SD), y 61.1 (10.03) 61.8 (9.42) 61.2 (10.05)
Male, n (%) 142 (61) 144 (61) 145 (62)
Weight, mean (SD), kg 94.5 (18.30) 95.5 (18.29) 97.0 (19.14)
BMI, mean (SD), kg/m2 32.7 (4.99) 32.9 (4.98) 33.0 (5.04)
Diabetes, n (%) 171 (73) 172 (73) 171 (73)
Baseline lipid parametersa
MARINE n ¼ 75 n ¼ 70 n ¼ 73
TG, mg/dL 679.5 (268.0) 660.5 (304.0) 706.0 (413.0)
LDL-C, mg/dL 90.0 (45.0) 81.0 (61.0) 81.0 (56.0)
Non-HDL-C, mg/dL 225.0 (93.0) 211.5 (77.0) 230.0 (85.0)
VLDL-C, mg/dL 122.0 (101.0) 121.5 (59.0) 130.0 (81.0)
VLDL-TG, mg/dL 521.0 (352.0) 506.0 (447.0) 549.0 (453.0)
ApoB, mg/dL 121.0 (34.0) 117.5 (35.0) 118.0 (39.0)
ANCHOR n ¼ 82 n ¼ 84 n ¼ 86
TG, mg/dL 255.8 (90.0) 262.5 (83.3) 264.3 (77.5)
LDL-C, mg/dLb 78.0 (22.0) 83.0 (22.0) 80.0 (29.0)
Non-HDL-C, mg/dL 122.0 (32.0) 124.5 (31.5) 124.0 (29.0)
VLDL-C, mg/dLb 43.5 (19.0) 41.0 (20.0) 41.0 (16.0)
VLDL-TG, mg/dLb 195.5 (102.0) 192.0 (86.0) 197.0 (89.0)
ApoB, mg/dL 88.5 (24.0) 91.0 (19.0) 92.0 (22.0)
ITT, intent to treat.
a Data are presented as medians (interquartile ranges) for baseline lipid parameter values. Baseline RLP-C levels are shown in Table 2. To convert from mg/dL to the In-
ternational System unit of mmol/L, multiply cholesterol by 0.0259 and multiply TG by 0.0113. To convert ApoB levels to the International System unit of g/L, multiply by 0.01.
b Data shown for 82 patients in the icosapent ethyl 4 g/day group, 83 patients in the icosapent ethyl 2 g/day group, and 85 patients in placebo group.
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(p¼ 0.02; n¼ 19) versus placebo (Fig. 2 and Table 2). When grouped
by baseline TG level, icosapent ethyl 4 g/day signiﬁcantly reduced
directly measured RLP-C levels by 37.5% in patients with baseline
TG levels >750 mg/dL (>8.48 mmol/L; p ¼ 0.02; n ¼ 28) versus
placebo; icosapent ethyl 4 g/day also reduced directly measured
RLP-C levels in patients with baseline TG levels 750 mg/dL
(8.48 mmol/L) versus placebo, although this reduction only
approached signiﬁcance (26.1%; p ¼ 0.06; n ¼ 47) (Table 2).
3.3. ANCHOR
Icosapent ethyl 4 g/day signiﬁcantly reduced median levels of
directly measured RLP-C by 25.8% (p ¼ 0.0001) overall compared
with placebo (Fig. 1 and Table 2). The effect of icosapent ethyl 4 g/
day on directly measured RLP-C levels was statistically signiﬁcant
versus placebo in patients with TG values below or above the study-
wide baseline median of 259 mg/dL (2.93 mmol/L); icosapent ethyl
4 g/day reduced directly measured RLP-C levels by 22.2% in pa-
tients with TG levels below the median (p ¼ 0.03; n ¼ 42) and
by 30.6% in those with TG levels above the median (p ¼ 0.001;
n ¼ 40) (Table 2). When evaluated by statin regimen intensity,
icosapent ethyl 4 g/day signiﬁcantly reduced directly measured
RLP-C levels by 26.7% (p < 0.001; n ¼ 77) versus placebo when
used with a medium- or higher-intensity statin regimen, whereas
changes were not statistically signiﬁcant versus placebo when ico-
sapent ethyl 4 g/daywas usedwith a lower-intensity statin regimen
(p ¼ 0.5; n ¼ 5) (Table 2).
3.4. Correlation analyses
Calculated RLP-C levels from both the MARINE and ANCHORstudies correlated with directly measured RLP-C levels
(r ¼ 0.63e0.92; p < 0.0001 for all) in analyses of values at baseline,
week 12, and percent change from baseline. In ANCHOR, directly
measured RLP-C had higher correlations with calculated values that
were derived from LDL-C measured with beta-quantiﬁcation at
baseline and follow-up (0.79 and 0.91, respectively) compared with
the LDL-C derived by the Friedewald equation (0.63 and 0.76)
(Table 3). In MARINE and ANCHOR, similar percent changes from
baseline versus placebo were seen for directly measured and
calculated RLP-C using LDL-C measured by beta-quantiﬁcation,
with a larger discrepancy between results observed in ANCHOR
between directly measured and calculated RLP-C when using LDL-C
derived by the Friedewald equation (Table 3).
4. Discussion
High RLP-C or remnant cholesterol levels are strong markers of
coronary risk and are likely causal factors for ischemic heart disease
[3,6,21,22]. The present analysis examined the effects of icosapent
ethyl on directly measured and calculated RLP-C levels in patients
with very high TG levels with or without concomitant statin ther-
apy from the MARINE study and in patients with high TG levels
despite statin therapy from the ANCHOR study. Previous analyses
reported that icosapent ethyl 4 g/day signiﬁcantly lowered TG, non-
HDL-C, ApoB, and ApoC-III levels and decreased LDL particle
number compared with placebo (i.e., potentially reducing LDL
atherogenicity) without increasing LDL-C levels [13,14,23,24]. The
present report demonstrates that icosapent ethyl signiﬁcantly re-
duces RLP-C compared with placebo in patients from the MARINE
and ANCHOR studies as measured directly via an immunosepara-
tion assay or when calculated. In these studies, icosapent ethyl 4 g/
day reduced RLP-C across a wide range of baseline TG levels, with
Table 2
Change from baseline to week 12 in directly measured RLP-C levels in patients from the MARINE and ANCHOR studies.
Directly measured RLP-C concentrationa Median change from baseline in
RLP-C concentration vs. placebob
Icosapent ethyl 4 g/day Icosapent ethyl 2 g/day Placebo Icosapent ethyl
4 g/day
Icosapent ethyl
2 g/day
Baseline,
mg/dL
End of
treatment,
mg/dL
Change,
%
Baseline,
mg/dL
End of
treatment,
mg/dL
Change,
%
Baseline,
mg/dL
End of
treatment,
mg/dL
Change,
%
%, p %, p
MARINE n ¼ 76 n ¼ 73 n ¼ 75
29.8
0.0041
14.9
0.1528
ITTc n ¼ 75 n ¼ 70 n ¼ 73
45.0
(53.0)
38.0
(45.0)
16.1
(86.5)
43.0
(37.0)
44.5
(38.0)
þ5.8
(85.5)
47.0
(58.0)
58.0
(90.0)
þ14.2
(105.4)
Current statin use
No n ¼ 56 n ¼ 52 n ¼ 56
21.4
0.0456
8.5
0.4421
45.0
(55.5)
39.5
(48.5)
16.6
(85.9)
45.0
(34.5)
44.5
(36.0)
þ3.0
(67.6)
50.5
(61.0)
54.5
(77.5)
þ7.0
(107.0)
Yes n ¼ 19 n ¼ 18 n ¼ 17
56.8
0.0198
41.6
0.1511
37.0
(45.0)
33.0
(27.0)
16.1
(136.4)
31.5
(47.0)
46.5
(50.0)
þ29.2
(108.0)
40.0
(38.0)
65.0
(124.0)
þ54.3
(116.9)
Baseline TGd
750 mg/dL n ¼ 47 n ¼ 42 n ¼ 41
26.1
0.0570
7.3
0.6554
34.0
(30.0)
29.0
(28.0)
8.8
(100.0)
27.5
(23.0)
32.5
(23.0)
þ18.2
(85.8)
30.0
(21.0)
33.0
(31.0)
þ19.0
(95.5)
>750 mg/dL n ¼ 28 n ¼ 28 n ¼ 32
37.5
0.0196
25.4
0.1016
89.5
(109.0)
68.5
(73.0)
25.4
(59.7)
66.0
(51.5)
65.0
(35.5)
10.7
(72.5)
90.5
(75.5)
100.5
(89.5)
þ5.7
(111.1)
ANCHOR n ¼ 226 n ¼ 234 n ¼ 227
25.8
0.0001
16.7
0.0153
ITTc n ¼ 82 n ¼ 84 n ¼ 86
13.5
(6.0)
10.0
(6.0)
24.0
(45.5)
15.0
(7.0)
11.0
(7.0)
11.1
(40.0)
14.0
(7.0)
13.0
(9.0)
þ8.0
(66.9)
Statin intensitye
Lower n ¼ 5 n ¼ 7 n ¼ 6
11.9
0.5228
2.7
0.8303
16.0
(3.0)
15.0
(5.0)
29.2
(33.3)
15.0
(6.0)
11.0
(9.0)
11.1
(21.1)
15.0
(6.0)
11.0
(24.0)
19.4
(105.1)
Medium and
higher
n ¼ 77 n ¼ 77 n ¼ 80
26.7
0.0002
17.3
0.0135
13.0
(6.0)
10.0
(6.0)
23.1
(45.5)
15.0
(7.0)
11.0
(7.0)
11.1
(42.3)
14.0
(7.0)
13.0
(8.5)
8.7
(66.5)
Study-wide median TG (259 mg/dL)f
<259 mg/dL n ¼ 42 n ¼ 40 n ¼ 37
22.2
0.0263
16.4
0.1092
11.0
(4.0)
9.0
(5.0)
16.0
(47.6)
11.5
(5.0)
11.0
(3.5)
8.1
(37.4)
11.0
(5.0)
12.0
(7.0)
þ9.1
(58.2)
259 mg/dL n ¼ 40 n ¼ 44 n ¼ 49
30.6
0.0010
18.0
0.0658
17.0
(5.5)
11.0
(6.5)
31.3
(37.6)
18.0
(8.0)
13.5
(7.0)
17.4
(37.2)
16.0
(4.0)
16.0
(11.0)
þ7.7
(64.1)
ITT, intent to treat.
a Data are presented as medians (interquartile ranges) for endpoint values. To convert from mg/dL to the International System unit of mmol/L, multiply cholesterol by
0.0259 and multiply TG by 0.0113.
b Median percent changes vs placebo are Hodges-Lehmann medians.
c Patients from ITT populations with RLP-C measurements.
d Per study protocol, patients in MARINE were stratiﬁed at randomization by baseline TG level 750 mg/dL and >750 mg/dL.
e Lower-intensity statin regimens: simvastatin 5e10 mg; medium- and higher-intensity statin regimens: rosuvastatin 5e10 mg, atorvastatin 10e20 mg, simvastatin
20e40 mg, simvastatin 10e20 mg plus ezetimibe 5e10 mg, rosuvastatin 20e40 mg, atorvastatin 40e80 mg, simvastatin 80 mg, simvastatin 40e80 mg plus ezetimibe
5e10 mg.
f Study-wide median represents the median of patients assessed in the 4 g/day, 2 g/day, and placebo groups.
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TG levels.
As statins are the cornerstone of lipid-lowering therapy, it is
worth noting that icosapent ethyl 4 g/day reduced RLP-C with or
without concomitant statin therapy in theMARINE study and in the
statin-treated patients in the ANCHOR study. In the latter study, the
reductions in RLP-C with icosapent ethyl 4 g/day appeared greater
in patients receiving medium-to higher-intensity statin regimens
than in patients receiving lower-intensity statin regimens. How-
ever, small sample size may be a limiting factor in the subgroup
analyses of patients receiving lower-intensity statin regimens in
the ANCHOR study, and of patients receiving statin therapy in the
MARINE study. The medium- and higher-intensity statin regimens
used in this analysis correspond with current recommendations for
statin therapy [25,26].Results of the present analysis expand on previously reported
results in patients with type 2 diabetes in the ANCHOR study,
showing that treatment with icosapent ethyl 4 g/day reduced
directly measured RLP-C levels by25% versus placebo (p < 0.01) in
this patient subset [27]. Other prescription omega-3 fatty acid
products, including another pure EPA product from Japan, as well as
products containing both EPA and docosahexaenoic acid, have also
been reported to reduce RLP-C levels in plasma at moderate to high
doses [27e33].
Residual cardiovascular risk can persist in patients with elevated
TG and RLP-C levels even after lowering of LDL-C levels [1,6,7].
Some of this residual risk may be explained by elevated remnant
cholesterol levels. Notably, standard measurements of TG levels or
LDL-C calculations do not account for this atherogenic cholesterol
content [34]. Cholesterol-rich remnant lipoprotein particles may
Fig. 1. Median percent change from baseline to week 12 vs. placebo in directly
measured RLP-C levels in patients from the MARINE and ANCHOR studies. Median
differences in percent changes vs. placebo are Hodges-Lehmann medians. *p < 0.01;
yp ¼ 0.0001; zp < 0.05; NS, not signiﬁcant; RLP-C, remnant-like particle cholesterol.
Fig. 2. Median percent change from baseline to week 12 vs. placebo in directly
measured RLP-C levels by statin use in patients from the MARINE study. Median
differences in percent changes vs. placebo are Hodges-Lehmann medians. *p < 0.05;
NS, not signiﬁcant; RLP-C, remnant-like particle cholesterol.
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with low-density lipoproteins (LDLs) [35]. RLP-C crosses the
endothelial barrier and may become trapped in the subendothelial
space preferentially to LDL-C, possibly due to the larger size of the
remnant particles [34], but unlike LDL particles, remnant particles
do not require oxidative modiﬁcation for uptake and can be taken
up in an unregulated fashion by macrophages [1]. RLP-C then
contributes to multiple steps in the development and progression
of atherosclerosis including endothelial dysfunction, foam cell
formation, and vascular inﬂammation [35e37]. RLP-C may have
pro-inﬂammatory properties and may cause endothelial dysfunc-
tion via actions on endothelial nitric oxide synthase [37]. Remnant-
like lipoprotein particles can induce endothelial dysfunction,
including impaired endothelial vasodilatation and abnormalendothelial secretion, thereby contributing to development of
atherosclerosis [37]. RLP-C levels also correlate with the vulnera-
bility of coronary plaques for rupture [38]. Thus, add-on therapy to
a statin may be needed to address residual cardiovascular risk. The
recent IMPROVE-IT outcomes study demonstrated that statin add-
on therapy can help address residual cardiovascular risk and that
lower LDL-C levels are associated with lower risk [39,40]. The
present results show that, compared with placebo, icosapent ethyl
lowers RLP-C levels in statin-treated patients in addition to its
previously reported reductions in TG, non-HDL-C, ApoB, and ApoC-
III levels and LDL particle number without increasing LDL-C levels.
These ﬁndings suggest that icosapent ethyl 4 g/day may provide a
beneﬁcial option in a statin-treated patient population such as that
of ANCHOR. The ongoing REDUCE-IT trial (NCT01492361) is eval-
uating whether icosapent ethyl 4 g/day will reduce cardiovascular
events when used as an adjunct to statin therapy in patients with
persistently high TG levels who have a high risk of future cardio-
vascular events [41]. It should be noted that icosapent ethyl is not
approved by the United States Food and Drug Administration to
reduce the risk of coronary heart disease; the effect of icosapent
ethyl on the risk of cardiovascular mortality and morbidity has not
been determined.
As noted earlier, different methods (calculated, vertical auto
proﬁle testing, and immunoseparation) may be used to measure
RLP-C, but these methods currently lack standardization. A recent
study found that reductions observed with one method can be
expected to occur across all methods, but RLP-C deﬁned by
immunoseparation and vertical auto proﬁle testing may differ in
mass and response to pharmacologic intervention [4]. Thus, stan-
dardization of measurement methods may be needed for use of
RLP-C in assessing cardiovascular risk [4]. In our correlation ana-
lyses of calculated RLP-C versus directly measured RLP-C, we found
strong correlations in baseline, 12-week, and percent change from
baseline analyses, despite differences in the amount of RLP-C re-
ported by each method. Furthermore, we also found statistically
signiﬁcant correlations between directly measured RLP-C and
calculated RLP-C when RLP-C was derived from LDL-C values based
on either the Friedewald equation for patients with TG levels
<400 mg/dL (<4.52 mmol/L) or based on beta-quantiﬁcation
wherein the cholesterol content of LDL is directly measured.
While direct RLP-C measurements require a speciﬁc test that uti-
lizes a two-step immunoseparation procedure, clinicians can
quickly calculate RLP-C from a standard lipid panel by subtracting
LDL-C from non-HDL-C [3]. These methods, however, do not pro-
duce identical values; yet, in clinical practice, change in calculated
RLP-C may still provide a useful and readily accessible estimation of
how interventions such as icosapent ethyl may be impacting a
patient's remnant cholesterol burden. Although direct measure-
ments of RLP-C in this study had a better correlation to calculated
RLP-C when using LDL-C measured with beta quantiﬁcation, RLP-C
calculated using Friedewald-derived LDL-C may represent an easily
accessible and inexpensive means in clinical practice to monitor
approximate changes in RLP-C for patients with TG < 400 mg/dL
(<4.52 mmol/L). Large prospective clinical outcome studies are
needed to fully assess the effects of icosapent ethyl on remnant
cholesterol.
Mechanisms by which icosapent ethyl may decrease RLP-C have
not yet been fully elucidated but may result from a reduction in
VLDL particle number through reduced hepatic release and/or
increased plasma clearance. The potential mechanisms of action of
EPA include increased b-oxidation; inhibition of acyl-CoA:1,2-
diacylglycerol acyltransferase; decreased lipogenesis in the liver;
and increased plasma lipoprotein lipase activity [42].
In addition to limitations mentioned earlier, it should be noted
that although the data are not pooled, they come from two different
Table 3
Correlation analysis of calculated RLP-C vs. directly measured RLP-C levels.
Population Correlation between calculated and directly measured RLP-Ca Median change from baseline in RLP-C
concentration for icosapent ethyl 4 g/day
vs. placebob
Baseline r value,
p value
End of treatment r
value, p value
% Change r value,
p value
Directly measuredc %,
p value
Calculated %,
p value
MARINE
Calculated RLP-C based on measured LDL-Cd n ¼ 224
0.88
<0.0001
n ¼ 218
0.92
<0.0001
n ¼ 218
0.84
<0.0001
n ¼ 76e
29.8
0.0041
n ¼ 76g
28.9
0.0002
ANCHOR
Calculated RLP-C based on measured LDL-Cd n ¼ 250
0.79
<0.0001
n ¼ 250
0.91
<0.0001
n ¼ 250
0.73
<0.0001
n ¼ 82e
25.8
0.0001
n ¼ 82g
31.7
<0.0001
Calculated RLP-C based on calculated LDL-Cf n ¼ 239
0.63
<0.0001
n ¼ 224
0.76
<0.0001
n ¼ 216
0.74
<0.0001
n ¼ 74g
16.6
0.0009
a Correlation analyses were conducted on pooled data from the icosapent ethyl and placebo groups. RLP-C was calculated as TC  (HDL-C)  (LDL-C) using measured or
calculated LDL-C.
b Median differences in percent changes with icosapent ethyl 4 g/day vs placebo are Hodges-Lehmann medians.
c Directly measured values are carried over from Table 2 for comparison.
d Calculated RLP-C levels were based on LDL-C levels as directly measured using beta-quantiﬁcation.
e MARINE: n ¼ 76 for icosapent ethyl 4 g/day, n ¼ 75 for placebo; ANCHOR: n ¼ 82 for icosapent ethyl 4 g/day, n ¼ 86 for placebo.
f Calculated RLP-C levels were based on LDL-C levels attained via the Friedewald equation (LDL-C ¼ TC  [HDL-C]  [TG/5]) in patients with TG levels <400 mg/dL
(<4.52 mmol/L).
g MARINE (LDL-C measured): n ¼ 76 for icosapent ethyl 4 g/day, n ¼ 75 for placebo; ANCHOR (LDL-C measured): n ¼ 82 for icosapent ethyl 4 g/day, n ¼ 85 for placebo;
ANCHOR (LDL-C calculated): n ¼ 74 for icosapent ethyl 4 g/day, n ¼ 68 for placebo.
C.M. Ballantyne et al. / Atherosclerosis 253 (2016) 81e8786studies with patient populations that differed in terms of lipids
(e.g., baseline TG levels were higher in MARINE than in ANCHOR by
design), demographics (e.g., MARINE was an international study,
ANCHOR was conducted solely in the United States), and medica-
tion use (e.g., statin use was allowed in MARINE and required in
ANCHOR).
In summary, icosapent ethyl 4 g/day, as compared with placebo,
signiﬁcantly reduced RLP-C in addition to its previously described
effects in lowering TG, non-HDL-C, ApoB, and ApoC-III levels and
LDL particle number without raising LDL-C levels. This analysis
extends the ﬁndings to date regarding the potentially beneﬁcial
lipid effects of icosapent ethyl in patients with elevated TG levels,
including those on statin therapy. The ongoing REDUCE-IT trial will
help to clarify whether the improvements in RLP-C and other
atherogenic parameters seen with high-purity prescription EPA at
4 g/day will translate to a reduction in major cardiovascular events
in statin-treated patients with persistent hypertriglyceridemia.Conﬂict of interest
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